Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells
Authors:
- 1 July 1997
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 32 (2) , 106-114
Abstract
BACKGROUND We investigated modulation of androgen receptor (AR) activity in prostatic tumor cells by lutenizing hormone-releasing hormone (LHRH)-induced increase of the intracellular cyclic adenosine monophosphate (cAMP) level. METHODS AR transactivation activity was assessed in transiently transfected DU-145 and in LNCaP cells. RESULTS LHRH and cAMP derivative, respectively, induced reporter gene activity to about 15% of the maximal level in DU-145 cells transfected with an AR expression vector and an androgen-inducible reporter gene. LHRH or the cAMP analogue acted synergistically in combination with low concentrations of androgen thus lowering the androgen concentration required for maximal AR activation by a factor of 100. A similar activation of the AR by cAMP analogue was observed in LNCaP cells when enhancement of androgen-induced secretion of prostate-specific antigen was determined. The two nonsteroidal antiandrogens hydroxyflutamide and Casodex (R) inhibited reporter gene activity. CONCLUSIONS The AR is synergistically activated by low doses of androgen and LHRH or the second messenger cAMP. This may have implications for the treatment of advanced prostate cancer. Prostate 32:106–114, 1997.Keywords
This publication has 28 references indexed in Scilit:
- Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cellsThe Prostate, 1996
- Mutant androgen receptors in prostatic tumors distinguish between amino‐acid‐sequence requirements for transactivation and ligand bindingInternational Journal of Cancer, 1995
- When tamoxifen turns bad.Endocrinology, 1995
- Case Reports: Withdrawal Phenomenon With the Antiandrogen CasodexJournal of Urology, 1995
- Agonists, but not antagonists, alter the conformation of the hormone-binding domain of androgen receptor.Endocrinology, 1994
- Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1993
- Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptorsBiochemistry, 1992
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assaysJournal of Immunological Methods, 1983
- Isolation of a human prostate carcinoma cell line (DU 145)International Journal of Cancer, 1978